These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 30528265)

  • 1. DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
    Li J; Yu T; Yan M; Zhang X; Liao L; Zhu M; Lin H; Pan H; Yao M
    Exp Cell Res; 2019 Jan; 374(2):304-314. PubMed ID: 30528265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.
    Gu MM; Gao D; Yao PA; Yu L; Yang XD; Xing CG; Zhou J; Shang ZF; Li M
    Cancer Sci; 2018 Dec; 109(12):3783-3793. PubMed ID: 30281878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells.
    Zhong B; Zheng J; Wen H; Liao X; Chen X; Rao Y; Yuan P
    Genes Genomics; 2022 Sep; 44(9):1071-1079. PubMed ID: 35353342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ubiquitin-associated (UBA) domain of SCCRO/DCUN1D1 protein serves as a feedback regulator of biochemical and oncogenic activity.
    Huang G; Towe CW; Choi L; Yonekawa Y; Bommeljé CC; Bains S; Rechler W; Hao B; Ramanathan Y; Singh B
    J Biol Chem; 2015 Jan; 290(1):296-309. PubMed ID: 25411243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
    Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-κB pathway.
    Li Y; Deng L; Zhao X; Li B; Ren D; Yu L; Pan H; Gong Q; Song L; Zhou X; Dai T
    J Pathol; 2018 Nov; 246(3):366-378. PubMed ID: 30043491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-7 inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells by targeting FAK through ERK/MAPK signaling pathway.
    Cao Q; Mao ZD; Shi YJ; Chen Y; Sun Y; Zhang Q; Song L; Peng LP
    Oncotarget; 2016 Nov; 7(47):77468-77481. PubMed ID: 27764812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer.
    Liu F; Cai Y; Rong X; Chen J; Zheng D; Chen L; Zhang J; Luo R; Zhao P; Ruan J
    Mol Cancer; 2017 Jul; 16(1):122. PubMed ID: 28716024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
    Wang S; Xu L; Che X; Li C; Xu L; Hou K; Fan Y; Wen T; Qu X; Liu Y
    FEBS Lett; 2018 Feb; 592(4):621-630. PubMed ID: 29364514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.
    De S; Holvey-Bates EG; Mahen K; Willard B; Stark GR
    Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34795058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
    Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
    Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHIP involves in non-small cell lung cancer prognosis through VEGF pathway.
    Tingting Q; Jiao W; Qingfeng W; Yancheng L; Shijun YU; Zhaoqi W; Dongmei S; ShiLong W
    Biomed Pharmacother; 2016 Oct; 83():271-276. PubMed ID: 27392029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DCUN1D1 and neddylation: Potential targets for cancer therapy.
    Paccez JD; Foret CLM; de Vasconcellos JF; Donaldson L; Zerbini LF
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167308. PubMed ID: 38885797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deguelin attenuates non-small cell lung cancer cell metastasis through inhibiting the CtsZ/FAK signaling pathway.
    Li W; Yu X; Ma X; Xie L; Xia Z; Liu L; Yu X; Wang J; Zhou H; Zhou X; Yang Y; Liu H
    Cell Signal; 2018 Oct; 50():131-141. PubMed ID: 30018008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC.
    Grant CE; Flis AL; Toulabi L; Zingone A; Rossi E; Aploks K; Sheppard H; Ryan BM
    Mol Oncol; 2024 Jun; 18(6):1631-1648. PubMed ID: 38572507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
    J Exp Clin Cancer Res; ; . PubMed ID: 32024543
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.